Board of Directors

Subject:	Learning from Death Mortality Surveillance	s Group (formerly e Group)– Q4 update	Date: 06/05/21	Date: 06/05/21							
Prepared By:	Dr John Tansley, Clinical Director for Patient Safety Chair Learning from Deaths Group Dr Nigel Marshall, Project Advisor to Medical Director										
Approved By:	David Selwyn, Medic	David Selwyn, Medical Director									
Presented By:	David Selwyn										
Purpose											
			Approval								
The purpose of	^t this paper is to prese	ent the Board of	Assurance	X							
Directors with a	a Summary of the imp	lementation of the	Update	X							
Learning from	Deaths Guidance, pro	viding an overview o	n Consider								
compliance aga	ainst the 90% standar	d to review all deaths	З,								
the lessons lea	rned and plans for 20	21/22									
Stratagia Ohio											
Strategic Obje	To promote and	To movimico the	Te continuouch	Ta ashiova							
outstanding	To promote and	not on tial of our	loarn and	hottor value							
care	and wellbeing	workforce	improve	Deller value							
Care		WOIKIOICE	mpiove								
x			X	X							
x Overall Level	of Assurance		X	x							
x Overall Level	of Assurance Significant	Sufficient	x Limited	x None							
X Overall Level	of Assurance Significant	Sufficient	x Limited	x None							
x Overall Level Risks/Issues	of Assurance Significant	Sufficient	x Limited	x None							
x Overall Level Risks/Issues Financial	of Assurance Significant Further information	Sufficient regarding IT platform	x Limited n for Mortality Revi	x None ew Tool							
x Overall Level Risks/Issues Financial Patient Impact	of Assurance Significant Further information	Sufficient regarding IT platforr ervices and care will	x Limited n for Mortality Revi be realised through	x None ew Tool the timely and							
x Overall Level Risks/Issues Financial Patient Impact	of Assurance Significant Further information t Improvements to se comprehensive rev	Sufficient regarding IT platforr ervices and care will riew of each death to	x Limited n for Mortality Revi be realised through maximise learning	x None ew Tool the timely and opportunities							
x Overall Level Risks/Issues Financial Patient Impact Staff Impact	of Assurance Significant Further information t Improvements to se comprehensive rev Changes to practic Process	Sufficient regarding IT platforr ervices and care will riew of each death to e and care will be ide	x Limited n for Mortality Revi be realised through maximise learning entified through the	x None ew Tool opportunities Mortality Review							
x Overall Level Risks/Issues Financial Patient Impact Staff Impact Services	of Assurance Significant Further information t Improvements to se comprehensive rev Changes to practic Process Changes to practic Process	Sufficient regarding IT platforr ervices and care will iew of each death to e and care will be ide e and care will be ide	x Limited m for Mortality Revi be realised through maximise learning entified through the entified through the	x None ew Tool othe timely and opportunities Mortality Review Mortality Review							
x Overall Level Risks/Issues Financial Patient Impact Staff Impact Services Reputational	of Assurance Significant Further information Improvements to se comprehensive rev Changes to practic Process Changes to practic Process Potential to impact	Sufficient regarding IT platforr ervices and care will riew of each death to e and care will be ide e and care will be ide on HSMR and SHM	x Limited n for Mortality Revi be realised through maximise learning entified through the entified through the	x None ew Tool the timely and opportunities Mortality Review Mortality Review							
x Overall Level of Risks/Issues Financial Patient Impact Staff Impact Services Reputational Committees/g	of Assurance Significant Further information t Improvements to se comprehensive rev Changes to practic Process Changes to practic Process Potential to impact roups where this ite	Sufficient regarding IT platforr ervices and care will riew of each death to e and care will be ide e and care will be ide on HSMR and SHMI m has been present	x Limited n for Mortality Revi be realised through maximise learning entified through the entified through the	x None ew Tool opportunities Mortality Review Mortality Review							
x Overall Level of Risks/Issues Financial Patient Impact Staff Impact Services Reputational Committees/g None	of Assurance Significant Further information Improvements to se comprehensive rev Changes to practic Process Changes to practic Process Potential to impact roups where this iter	Sufficient regarding IT platforr ervices and care will iew of each death to e and care will be ide e and care will be ide on HSMR and SHMI m has been present	x Limited n for Mortality Revi be realised through maximise learning entified through the entified through the	x None ew Tool opportunities Mortality Review Mortality Review							
x Overall Level of Risks/Issues Financial Patient Impact Staff Impact Services Reputational Committees/g None	of Assurance Significant Further information Further information Improvements to se comprehensive rev Changes to practic Process Changes to practic Process Potential to impact roups where this iter	Sufficient regarding IT platforr ervices and care will riew of each death to e and care will be ide e and care will be ide on HSMR and SHMI m has been present	x Limited n for Mortality Revi be realised through maximise learning entified through the entified through the	x None ew Tool opportunities Mortality Review							

This quarterly report provides an update on the work of the learning from deaths group during Q4 2020 (January to March 2021). We give details of our progress against actions identified in the Q3 report presented to Board in January.

 Our HSMR remains raised at 110.5 (data available to November 2020). The effects of the COVID pandemic are clear within this data and we outline our proposals for meeting the requirements of investigation of Hospital acquired COVID and learning from other COVID related mortality data. We continue to review our HSMR and SHMI data and work closely with Dr Foster to understand what drives the changes in our data Preliminary discussions with an alternative mortality intelligence provider CHKS have raised some interesting areas for further exploration

- An update on project work with clinical specialties that are historical or current mortality outliers is included as an addendum to this report
- Interim findings of our review of Trust Mortality Review Process and proposals for further actions. The COVID pandemic has significantly affected our ability to achieve our target of 90% reviews using the mortality tool. We have noted that the quality assurance of our Learning from Death processes requires strengthening and our proposals to address this are described
- Expansion of our Medical Examiner Service has allowed independent scrutiny of 97% of hospital deaths which partially mitigates this underachievement of the MRT target and a powerful example of learning from the process is provided.

1. COVID 19

As discussed in the Q3 report we are now starting to see the impact of the second wave of COVID on our mortality figures. Dr Foster is currently reporting on December 2020 but we have validated data to November (Fig 1) which shows the expected upturn. The peak from the first wave is also easily identifiable.

Figure 1 – HSMR Trend



The small number of "hospital identified" COVID 19 cases (positive tests more than 8 days following a negative test on admission) which were flagged early by our Medical Examiners did represent a national trend and we have had instruction from the National Patient Safety Team at NHS England/Improvement that all such deaths occurring from March 2021 should be investigated. Our agreed approach to this has two components. A nosocomial infection investigation carried out at ward level and a Structured Judgement Clinical Review carried out by the responsible Medial team. Any concerns raised by either of these processed will result in escalation through the Serious Incident framework. We feel strongly that this process should be extended to all nosocomial infection, not just COVID 19. Limitations of the current Mortality Review Tool discussed in the Q3 report represent an obstacle to capturing and triangulating learning. In the light of this, ICT has agreed to upgrade our incident reporting platform to DCIQ allowing our information can be viewed on a single connected platform. Following installation (ideally May 2021) the mortality review module will be a priority to allow this analysis and learning to begin. We have also identified a cohort of around 70 patients who are likely to have contracted COVID in hospital prior to February 2021. Following, and informed by, the priority prospective investigation we are planning a retrospective thematic review. We continue to log harms (including deaths) from a number of sources which may have been contributed to either

directly or indirectly by COVID and a dedicated member of staff in the Governance Support Unit has begun to analyse this information to detect learning.

2. Progress on actions in Q3

- On-going work with clinical, coding and Dr Foster colleagues has revealed no definite simple explanation for our raised HSMR although we have identified a number of areas where we feel our processes could be improved particularly in the case of Liver Disease (alcohol related) which remains an outlier.
- We have identified potential ways to improve our use of available data
- Review of our Learning from Deaths processes as described by the Mortality Management Policy and associated Mortality Review Tool to provide assurance that potential learning from deaths is identified in a timely and effective way has identified some areas of concern (see section 4) and we request an extension to the March 2021 deadline for implementation while we establish a realistic timescale for completion of this work
- Close working with our Medical Examiners has resulted in identification of a significant
 learning and improvement opportunity in caring for our patients with Learning Disabilities
- 3. Dr Foster Mortality Data



Figure 3.1 – HSMR Trend (rolling 12 months)

The Trust has a HSMR 110.5 in the year to November 2020 which is higher than the national/ regional average.

Figure 3.2 – HSMR Trend (rolling 12 months compared with regional peers)



We feel it is noteworthy that whilst our HSMR is raised it does not appear to be increasing, unlike those of our peer group.

Figure 3.3 – 5 year HSMR Trend



Looking back on the last 5 years of HSMR data shows that our position is relatively stable. Review and analysis of the data thus far has failed to show a specific reason as to why the Trust saw an initial upward trend (orange data points in 2019) leading to this and its continued elevated position. The impact of COVID 19 in April 2019 can also be seen on this figure

Figure 3.4 SHMI

ΗN	II - Summary H	lospital Mortali	ty Indic	ator										Prov	der			Regio	n		
												RK5 - SHERW	OOD FOREST H	OSPITAL	NHS FOUND		NHS ENGLAND MIDLANDS AND	EAST (NO	JRTH MID	ilan 🔻	
eri	00: Oct 19 - Se	p 20											Click to ena	ble be	poke pe	r					
								SI	IMI -	Publis	hed (With Over Dis	persion)					* click group name to filter;	click hea	der title l	o clear	
	Prov	ider		Denominator	Obs	Exp	Obs-	SHMI	Low	High	Site - All Diagnosis	Den	Obs Ex	5 SF	MI Low	High	SHMI Group	Obs	Fxn	SHMI	Lo
	Chesterfield Royal Hospital N	HS Foundation Trust		46.010	1.645	1,690	Exp -45	97.26	88.67	112.77	KING'S MILL HOSPITAL	54.165	1.915 1	220	7.92 86.2	115.89	Shini Group	003		2000	
	Nottingham University Hospi	tals NHS Trust		126,845	4,065	3,985	80	102.00	89.17	112.15	NEWARK HOSPITAL	380		10			Septicemia (except in labour), Shock	220	240.00	92.20	1
	Sherwood Forest Hospitals N Shrewshury And Telford Hose	HS Foundation Trust		54,545	1,920	1,965	-45	97.72	88.79	112.63							Cancer of bronchus, lung	45	30.00	144.72	
	University Hospitals Of Derby	And Burton NHS Foundati	on Trust	117,255	4,170	4,665	-495	89.39	89.22	112.08							Provide a setter setter		20.00		
	University Hospitals Of North	Midlands NHS Trust		124,535	4,105	4,005	100	102.54	89.17	112.15							secondary maignancies	25	30.00	84.05	1
																	Fluid and electrolyte disorders	25	25.00	110.02	
																	Acute myocardial infarction	20	20.00	100.63	-
																	Pneumonia	330	360.00	91.87	
																					-
																	Acute bronchitis	30	30.00	89.13	1
																	Gastrointestinal haemorrhage	40	30.00	140.27	
											120.0						Urinary tract infections	20	35.00	60.76	1
											80.0						Fracture of neck of femur (bio)	60	50.00	122.01	
				531,645	18,490	18,735	-245	98.69			40.0 20.0 0.0 attent attent			,	,						
	Deaths: In / Ou	t Hospital		531,645	18,490 Q	18,735 % Pallia	-245 tive C	98.69 Care Co	ding		40.0 20.0 0.0 R ²⁰⁶ R ²⁰⁸		Trend	/ Rate			SHMI Group - With	1 95%	CI (D	r Fost	er
,	Deaths: In / Ou In Hospital 0	t Hospital ut of Hospital	2.5	531,645	18,490 q % Prov	18,735 % Palliz	-245 Itive C Is with F	98.69 Care Co Palliative	ding Care C	Coding -	40.0 20.0 0.0 großer große	Jun 20	Trend , 12 Months to Jul 20 Aug	(Rate	20	•	SHMI Group - With	1 95% Obs	CI (D	r Foste	er
,	Deaths: In / Ou In Hospital 0	t Hospital ut of Hospital	2.5	531,645	18,490 9 % Prov	18,735 % Pallia rider Spel	-245 Itive C Is with F	98.69 Care Co Palliative	ding Care C	Coding -	40.0 20.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	Jun 20 96.75	Trend , 12 Months to Jul 20 Aug 97.57 97.5	/ Rate 20 Se 3 37	20 72 S	¢	SHMI Group - With	95% Obs	CI (D	r Fosti SHMI	er
•	Deaths: In / Ou In Hospital 0 2,750	t Hospital ut of Hospital 1,355	2.5 2.0 1.5	531,645	18,490 9 % Prov	18,735 % Palliz Hder Spel	-245 Itive C Is with F	98.69 Care Co Palliative	ding Care C	Coding -	400 200 00 80 ² gd ^{gg}	Jun 20 96.75	Trend , 12 Months to Jul 20 Aug 97.57 97.5	/ Rate 20 Se 39 97	20	¢MII	SHMI Group - With SHMI Group (93) Uver disease, alcohol-related	7 95% Obs 35	c CI (D Exp 20	r Foste SHMI 175.00	ter;
,	Deaths: In / Ou In Hospital O	t Hospital ut of Hospital 1,355	2.5 2.0 1.5 1.0	531,645	18,490 9 % Prov 2.0	18,735 % Palliz rider Spel	-245 Itive C Is with F	98.69 Care Co Palliative	ding Care C	Coding -	200 200 00 00 00 00 00 00 00 00 00 00 00	Jun 20 96.75	Trend , 12 Months to Jul 20 Aug 97.57 97.9 1.5% 3.5%	/ Rate 20 Se 3 97 6 3.	20 72 S	e Rate	SHMI Group - With SHMI Group (93) Uver disease, alcohol-related (65) Congestive heart failure,	7 95% Obs 35	cI (D	r Foste SHMI 175.00	er)
	Deaths: In / Ou In Hospital 0 2,750 2,945	t Hospital ut of Hospital 1,355 1,225	2.5 - 2.0 - 1.5 - 1.0 -	531,645	18,490 9 — % Prov 2.0	18,735 % Palliz rider Spel	-245 Ative C	98.69 Care Co Palliative	ding Care C	Coding -	200 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	Jun 20 56.75 1.5%	Trend 12 Months to Jul 20 Aug 97.57 97.57 3.5% 3.5%	/ Rate 20 Se 3 97 6 3.	20 72 S 34 Crus	iMI e Rate	SHMI Group - With SHM Group (3) Uver disease, alcohol-related (65) Congestive heart failure, nonhypertname,	7 95% Obs 35 90	CI (D	r Foste SHMI 175.00 112.50	er)
	Deaths: In / Ou In Hospital O 2,750 2,945	t Hospital ut of Hospital 1,355 1,225	2.5 2.0 1.5 - 1.0 - 0.5 -	531,645	18,490 9 % Prov 2.0	18,735 % Palliz ider Spel	-245 Itive C Is with F	98.69 Care Co Palliative	ding Care C	Coding -	400 200 200 200 200 200 200 200 200 200	Jun 20 96.75	Trend 12 Months to Jul 20 Aug 97.57 97.57 3.5% 1.5	/ Rate 20 Se 39 57	20 72 5 % Crut	e Rate	SHMI Group - With SHM Group (3) Uver diseas, stocholerlated (4) Congestive Next failure, mathight families	7 95% Obs 35 90	CI (D	r Foste SHMI 175.00 112.50	er,
	Deaths: In / Ou In Hospital = 0 2,750 2,545	t Hospital ut of Hospital 1,355 1,225	2.5 2.0 1.5 1.0 0.5 0.0	531,645	18,490 9 % Prov 2.0	18,735 % Palliz Ider Spel	-245 Itive C is with F	98.69 Care Co Palliative	ding Care C	Coding -	400 200 400 400 400 400 400 400 400 400	Jun 20 96.75 1.5%	Trend 12 Months to Jul 20 Aug 97.57 97.5 3.5% 1.5	/ Rate 20 Se 3 57 6 3.	20 72 S 75 Crut	e Rate	SHMI Group - With SHM Group (3) Iver disease, skoholestated (3) congestive set false, nonhypertensive (44) Acide cerebrowischer disease	0 95%	CI (D	r Fosto SHMI 175.00 112.50 105.00	er)
	Deaths: In / Ou In Hospital II O 2,750 2,945	t Hospital 1,355 1,225 1,085	2.5 2.0 1.5 1.0 0.5 0.0	531,645	18,490 ۹ % Prov 2.0 ج ^ن ²	18,735 % Palliz ider Spel	-245 Intive C Is with F	98.69 Care Co Palliative 2	ding Care C	Coding -	22 22 22 20 20 20 20 20 20 20 20 20 20 2	Jun 20 96.75 1.5%	Trend , 12 Months to Jul 20 Aug 97.57 97.5 1.5% 1.5	/ Rate 20 50 3 91 6 3	20 72 5 75 Crut	e Rato	SHMI Group - With SHM Group (3) Uver diseas, alcoharelated (6) Conjective heart falue, nonhigerteniue (6) Acute crestrowacular disease (31) Capits (fitosa), Other lower	0bs 35 90	CI (D	r Foste SHMI 175.00 112.50 105.00	
	Deaths: In / Ou In Hospital © O 2,750 2,945 1,500	t Hospital ut of Hospital 1,355 1,225 1,085	2.5 2.0 1.5 1.0 - 0.5 - 0.0	531,645 1.7	18,490 9 % Prov 2.0 ج ^{ر2}	18,735 % Palliz ider Spel	-245 s with F	98.69 Care Co Palliative 2 2	ding Care C	Coding -	200 00 00 00 00 00 00 00 00 00 00 00 00	Jun 20 96.75 1.5% R.E RTG	Trend , 12 Months to Jul 20 Aug 97.57 97.1 1.5% 1.5	/ Rate 20 5e 3 97 6 3	20 72 5 75 Crut	e Rato	SHMI Group - Wild SHM Group (1) Liver diseas, skohol-related (6) Congestive Neutraliane, norhippertensive (64) Andre crestbrowscular disease (11) Cyste Tibrosio, Other lower respiratory disease	95% Obs 35 90 105 15	CI (D Exp 20 80 100	r Foste SHMI 175.00 112.50 105.00	er,
	Deaths: In / Ou Initiospital 0 01 2,750 2,945 1,500 1,500	t Hospital ut of Hospital 1,355 1,225 2,085	2.5 2.0 1.5 1.0 0.5 0.0 50.0	531,645 1.7 ¢ ⁶	18,490 9 	18,735 % Palliz ider Spel	-245 ative C as with F	98.69 Care Cc Palliative 2 ci ²	care C 1 e Codir	Coding -	200 200 200 200 200 200 200 200 200 200	Jun 20 96.75 3.5% R.E RTG	Trend , 12 Months to 30 20 Aug 87.57 57.1 1.55% 1.55	/ Rate 20 Se 3 97 6 3	20 72 5 75 Crut	e Rate	SHMI Group - With SHM Group (3) love disease, skohol-related (6) Conjective heart failure, nonhipertensise (6) Acate creterovascular disease (81) Cyste fibrosis, Other lower respiratory disease (81) Pershinal and viscoral	95% Obs 35 90 105 15	CI (D Exp 20 80 100	r Fosta SHMI 175.00 112.50 105.00	
	Deaths: In / Ou In Hospital I O 2,750 I 1,500 I	t Hospital ut of Hospital 1,355 1,225 1,085 725	2.5 2.0 1.5 1.0 0.5 0.0 45.0 40.0	531,645	الله (18,490 9 2.0 یک الله (1997) 2.0	18,735 % Palliz ider Spel	-245 ative C as with F	98.69 Care Cc Palliative علی می	Care C 1 e Codir	coding -	200 200 200 200 200 200 200 200 200 200	Jun 20 96.75 3.554 R.E RTG RXW	Trend , 12 Montha to 19 757 97.57 1.55% 1.5	/ Rate	20 72 5 75 Crut	e Rate	SHMI Group - With SHM Group (3) Uver diseas, alcohol related (6) Congestie Australiane, nonhigertenive (6) Acto credrovascular disease (1) Cystic fibrosis, Other lower registricity disease (2) Prompteral and visceral abereschrosis	95% Obs 35 90 105 15 15	CI (D Exp 20 80 100 10 10	Pr Fost SHMI 175.00 112.50 105.00 150.00	
	Deaths: In / Ou In hospital 0 2,750 2,945 1,500 1,195	t Hospital ut of Hospital 1,355 1,225 1,085 725	2.5 2.0 1.5 1.0 0.5 50.0 45.0 50.0 45.0 50.0	531,645	عليم من المراجع من المراجع المراجع من مراجع من مراجع م مراجع المراجع ا مراجع المراجع ال	18,735 % Palliz ider Spel	-245 Intive C is with F	98.69 Care Co Palliative 2 cf ² ative Car	ding Care C 1 e Codir	coding -	200 200 200 200 200 200 200 200 200 200	Jue 20 55.75 RJE RTG RCW	Trend , 12 Months to 97,57 97,1 1,51% 1,5	/ Rate 20 50 9 91 1	20 72 5 75 Crut	e Rate	SHMI Group - With SHM Group (3) Ever disease, shoch-related (3) Orgentse has the false, nonhypertensive (44) Acids cerebrowscolar disease (43) Orgentse has the false, (44) Acids cerebrowscolar disease (43) Peripheral and viceral atheractorism.	95% Obs 35 90 105 15 15	CI (D Exp 20 80 100 10 10	Pr Fost SHMI 175.00 112.50 105.00 150.00	
	Deaths: In / Ou In Hospital I O 2,780 2,385 1,500 1,195 1,045	t Hospital ut of Hospital 1,355 1,225 1,085 725	2.5 2.0 1.5 1.0 0.5 0.0 45.0 45.0 45.0 45.0 35.0 35.0 35.0 30.0	531,645	اللہ 18,490 م پ ک ر پ ک ر ک ر ک ر ک ر ا	18,735 % Palliz vider Spel	-245 itive C is with F 235 \$	98.69 Care Co Palliative 2 cc ² ative Car	ding Care C 1 e Codir	Coding -	200 200 200 200 200 200 200 200 200 200	Jun 20 95.75 1.05 R.E RTG RXW RXS	Trend	/ Rate	20 72 S 72 Crut	e Rate	SHMI Group - With SHM Group (3) Uver disease, sicobi-related (6) Loog state heart fallere, nonhypertensive (6) Acute credrovascular disease (81) Optic floria, Oher tweer registrory disease (81) Priprist and viscential athemacilences (99) Acute and surgeother renal failure	95% Obs 35 90 105 15 15 50	CI (D) Exp 20 80 100 10 10 45	r Fost SHMI 175.00 112.50 105.00 150.00 150.00	
	Deaths: In / Ou II in riospital © Of 2,750 2,345 1,500 1,155 3,045	t Hospital ut of Hospital 1,355 1,085 725 1,080	2.5 2.0 1.5 1.0 0.5 50.0 50.0 50.0 50.0 50.0	331,645	18,490 9 	۱۹,735 Vo Palliz ider Spel	-245 tive C is with P 2.5 S th Pallie	98.69 Care Cc Palliative 2 cf ^d	ding Care C 1 e Codir	coding -	200 200 200 200 200 200 200 200 200 200	Jare 25 55,73 116 R.JE RTG ROW RKS	Trend , 12 Months to Jul 20 Aug 97.57 97.7 1.55% 1.5	/ Rate	20 72 5 72 Cruit	e Rate	SHMI Group - With SHM Group (3) Uver disase, skoheleitate (3) Projektra and visceral adverschivers. (3) Acate and ungeschief enail tature	95% Obs 35 90 105 15 50	CI (D Exp 20 80 100 10 10 45	Fr Fost SHMI 175.00 112.50 105.00 150.00 150.00 111.11	
	Deaths: In / Ou In Hospital I O 2,750 2,985 1,500 1,155 1,095	t Hospital ut of Hospital 1,355 1,225 1,085 725 1,020	2.5 2.0 1.5 1.0 0.5 0.0 50.0 40.0 35.0 30.0 25.0 20.0 50.0 15.0 10.0 50.0	531,645	18,490 9 % Prov 2.0 & ¹ % E 41.0	18,735 % Palliz ider Spel	-245 itive C is with F 2.5 > th Pallia	98.69 Care Cc Palliative Q ² ttive Car	ding Care C 1 e Codir	Coding - 1 ¢ ^C	200 200 200 200 200 200 200 200 200 200	Jun 20 95.75 JUS RUE RTG ROW R85 EX1	Trend , 12 Months to 24 20 Aug 97.57 97.3 35% 155	/ Rate	20 72 5 Crut	the Rate	SHMI Group - With SHM Group (3) love disease, skohol-related (6) (conjective heart failure, nonhippertaining (6) Acute creterovascular disease (81) (cytic fibrosis, Other lower respiratory disease (81) (cytic fibrosis, Other lower respiratory disease (81) (cytic and voluceal atheresciences) (99) Acute and voluceal atheresciences)	95% 35 30 105 15 50 20	CI () Exp 20 80 100 10 10 45 15	Pr Fost SHMI 175.00 112.50 105.00 150.00 111.11 133.33	
p 7 7	Deaths: In / Ou II In Hospital © O 2,770 2,945 1,500 1,195 1,095	t Hospital ut of Hospital 1,355 1,225 1,085 725 1,020 1,020	2.5 2.0 1.5 1.0 0.5 - 0.0 - 50.0 - - - - - - - - - - - - - - - - - -	531,445	18,490 9 	18,735 % Palliz ider Spel	-245 itive C is with F 2.5 S th Pallia a.0	98.69 Care Cc 2 2 allative c d d tive Car	ding Care C 1 e Codir	20ding 1 19	200 200 200 200 200 200 200 200 200 200	Jar 20 5577 13% RJE RTG ROV ROS RO1	Trend , 12 Months to 301 20 Aug 302 37 31, 335% 13	/ Rate	20 72 S 75 Crut	e Rate	SHMI Group - With SHM Group (3) Liver diseas, alcohol related (6) Jordestine beart failer, nothgentensive (6) Jordest cerebrowacular disease (81) Optic beart failer, (91) Acute and unspectified renal failure (91) Acute and unspectified renal failure (91) Acute and unspectified renal failure (91) Houtis, pinsumatheras, palmonary collagie (94) Hapatis, Wain Intellor, Other	b 95% Obs 35 90 105 115 50 20 20	CI (D Exp 20 80 100 10 10 45 15	r Fost SHMI 175.00 112.50 105.00 150.00 111.11 133.33	
	Deaths: In / Ou In hospital 0 0 2,750 2,945 1,500 1,155 1,945 1,945	t Hospital ut of Hospital 1,355 1,225 1,085 725 1,020 559	2.5 2.0 1.5 1.0 0.5 0.0 450 450 450 450 20.0 100 500 100 500	531,445	18,490 9 	18,735 % Palliz ider Spel	-245 itive C 0.5 S S S S S S S S S S S S S S S S S S S	98.69 Care Cc Palliative 2 c c c c c c c c c c c c c c c c c c	ding Care C 1 e Codir	Coding - 1 e r 1 g - 2 a	200 200 200 200 200 200 200 200 200 200	Jun 20 95,77 3,555 R.26 R.00 R00 R00 R00 R00 R01 R95	Trend , 12 Months to 14 A0 Arg 9737 013 1555 15	/ Rate 20 Se 9 9: 10 10 10 10 10 10 10 10 10 10 10 10 10	20 72 5 Cruit	e Rate	SHMI Group - Witth SHM Group (3) Uver disease, sichol-related (3) Orgenite heats and failer, nonhippertravive (4) Acts cerebrovascular disease (4) Orgenitaria and viscenal atheracicrosis (2) Product and viscenal atheracicrosis (2) Acts, you and you an	P5% Obs 35 90 105 15 50 20 20	Ct (D Exp 20 80 100 10 10 45 15	r Fost SHMI 175.00 112.50 105.00 150.00 111.11 133.33	er) 1 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 2 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1

The SHMI is 97.72 which is as expected with two significant outliers cancer of bronchus (which is significant because of the "out of hospital" element with the in hospital element remaining stable and has seen a decrease over the last three data points to November 20) and Liver disease (alcohol related) which is a known concern.

A summary of the project work with clinical teams can be found in an addendum to this report.

Data quality and analytic factors

Postcode issues-

 Postcodes have been missing from a proportion of our submitted data leading to an impact on deprivation coding. This issue was a result of a technical change to our PAS system changing our CDS submission. Refreshed data was submitted and whilst it is understood correction of this may have reduced our HSMR slightly but does not explain all of the variance.

Residual Codes

• Up to 50% of activity has not been assigned to one of the HSMR group sub-sets on two separate reporting months over the past year. This has led to Dr Foster being unable to provide a definitive monthly report with assurance of data, resulting in the inability to perform meaningful analysis and therefore the latest confirmed report is for February 2021 (November 2020 data). We have been assured by Dr Foster this should be rectified for April 2021 reporting although confirmation of accuracy is awaited before using this in our internal analysis and discussion. Initial investigation suggests that the data are complete within the Trust and the problem lies externally. A solution to this would be to put a 1 month delay on our reporting schedule- something that Dr Foster does with other clients.

Information and Analysis provision

- Our contract with Dr Foster is coming up for renewal (August 2021). Use of the dashboard toolkit within the organisation, has been limited although and much of the functionality is dependent on a "request and response" agreement with Dr Foster which is part of our contract. The ideal situation would be to have greater data control in carrying out initial scoping /self- analysis prior to any request. A new Dr Foster Consultant has just taken over our Trust's data (2nd in 2 years) which gives us the opportunity to review this working arrangement. A priority for this work will be provision of specialty-specific mortality data available to the clinical teams in addition to the high level aggregate data provided by HSMR.
- CHKS is an alternative mortality data analysis provider and contact has been made with other Trusts who have made a switch from Dr Foster.
 - o General feedback is extremely positive, citing:
 - Enhanced usability, greater functionality, and bespoke analytics.
 - Potential for full API control therefore allowing business / information intelligence teams to self-analyse more effectively.
 - Lower comparative cost

Figure 3.5 CHKS HSMR trend



Fig 3.5 Shows HSMR data for SFH (green) plotted using the CHKS toolkit against that of another CHKS client (blue). The COVID peaks are again easily identifiable but of note our HSMR is otherwise consistently below 100. This raises the possibility that the way our data are handled is contributing to our HSMR outlier status. We feel that this is worthy additional investigation and input from internal SFH data analysts/ intelligence would be of value here.

Figure 4.1 Learning from Deaths Dashboard at Q4 2020/21								
Inpatient & Emergency Department		Reviews	%	Avoidability				
Deaths	Total	completed	Reviewed	Assessments				
Jan-21	308	200	64.9	14				
Feb-21	185	116	62.7	8				
Mar-21	127	51	40.2	Not recorded				
Qtr 1	369	312	84.6	25				
Qtr 2	307	217	70.7	9				
Qtr 3	484	377	77.9	36				
Qtr 4	620	367	59.2	22				
Year 20/21	1158	1272	71.5%	92				
Year 19/20	1514	1314	86.79%	41				
Year 18/19	1446	1267	87.62%	11				
Year 17/18	1550	1300	83.87%	21				

4. Review of Deaths and Structured Judgement Review (SJR)

Performance of reviews recorded on the mortality review tool against the 90% target remains below target. Increasing number of deaths and clinical workload during the second COVID wave are continuing contributors resulting in a delay. Screening of cases for SJR Triggers (learning disabilities, mental health, SUI, Hospital Acquired COVID etc.) has been formalised as part of the ME scrutiny process. 97% of cases (604) were scrutinised by MEs in Q4 and in order to improve traceability we are logging any SJR requests via our Datix platform and requiring the output of the MRT to be added to the Datix platform.

We are assured that any cases which require compulsory SJRs will have been identified to the parent teams and that these cases will be monitored against the same 6 week timescale as other Datix incidents satisfying the need for an audit structure to capture SJR activity and provide the information sought by the 360 assurance report. Once the dedicated Mortality Review module is built in DCIQ this will improve user experience as this workaround is somewhat cumbersome.

The new SJR panel described in the Q3 comprising Medical, Nursing, Allied Health Professional, ME and representatives of the LFD group convened in March. We reviewed the existing Trust processes and discussed where this panel would fit in. We agree a requirement for training in SJR methodology which was provided by Dr Bahl the lead Medical examiner.

During this training it has become apparent that our Trust mortality review tool does not explicitly follow the Royal College of Physicians methodology which raises questions regarding training received by those using the current tool. Whilst the data suggest that the number of SJRs and avoidability assessments is increasing we have limited confidence about the quality and consistency of this process, so propose this is worthy of further scrutiny to gain that assurance. This should also ensure that the process dovetails with other Trust governance structures and for nococomial COVID investigations, utilising our existing SI methodology, appears more appropriate. The new DCIQ platform will be a significant enabler to this work but requires an extended timeline to ensure robust and reliable delivery.

5. Medical Examiner (ME) Role

The Medical Examiner service continues to develop and whilst maintaining its independence we feel that the scrutiny process is making an increasingly valuable contribution to our Learning from Deaths process. Our lead medical examiner as described above is playing an active role in our SJR training. A small number of patients with learning disabilities were flagged for SJR by the medical examiners as they did not appear to have had input from the safeguarding team.

Whilst we are confident that these cases are being identified and notified for the appropriate LeDeR review when they have died we have identified a potential gap in our processes for identifying these patients to the Learning Disability Specialist Nurse on admission. We have been able to rapidly pull together a group of stakeholders, undertake a process mapping exercise and describe a Standard Operating Procedure which is currently going through the Trust Governance Structure for approval.

6. Plans for Q4 & 2021/22

- Complete review and refresh of mortality management policy and mortality review tool/ process including build on DCIQ.
- Implement SJCR Faculty and monitor appropriate training to ensure consistency of quality of SJR to support governance of our mortality processes and learning from deaths.
- Continue clinical project work in those areas which have been identified as mortality outliers
- Continue to improve our use of available mortality data/ intelligence working with external providers and support from SFH data analysts.